News


December 19th, 2019

Qu Biologics Completes Enrollment in First Stage of Phase 2 Clinical Trial in Moderate to Severe Crohn’s Disease

VANCOUVER, British Columbia – Dec. 18, 2019 (GLOBE NEWSWIRE) — Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunotherapy platform designed to restore innate immune function, is pleased to announce the completion of enrollment for the first stage of the RESTORE clinical trial, “A Phase 2, Multi-center, Randomized, Double-Blind, Placebo-Controlled […]

READ MORE >
July 23rd, 2019

Qu Biologics publishes potentially paradigm-shifting results of their first randomized-placebo controlled trial for the treatment of Crohn’s disease

Vancouver, British Columbia – July 23rd, 2019 – Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of microbial-based immunotherapies designed to restore the body’s innate immune system, is pleased to report that the results of their first randomized-placebo controlled trial (RCT) in patients with moderate-to-severe Crohn’s disease (CD) […]

READ MORE >
July 25th, 2018

Qu Biologics enrolls the first patient in new Phase 2 Crohn’s disease clinical trial

Vancouver, British Columbia – July 25, 2018 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce that the first patient in the  RESTORE Phase 2 clinical trial for patients with moderate to severe Crohn’s disease has been […]

READ MORE >
July 9th, 2018

Crohn’s disease clinical trial – Now enrolling

Qu Biologics is now recruiting Canadian residents to participate in the first stage of a Phase 2 clinical trial of QBECO SSI in the treatment of adults living with moderate to severe Crohn’s disease. The aim of this trial is to further establish the safety and efficacy of the investigational drug QBECO SSI for the […]

READ MORE >
May 16th, 2018

Leading-edge Scientists in Innate Immunity Join Qu Biologics’ Scientific Advisory Board

Vancouver, British Columbia – May 15th, 2018 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce the addition of four members to Qu’s Scientific Advisory Board (SAB), consisting of world leading experts in the fields of innate […]

READ MORE >
May 10th, 2018

Qu Biologics SSIs featured in Inside Tract magazine

Qu Biologics’ paradigm shifting approach to IBD is featured in the March April 2018 issue of the Gastrointestinal Society’s ‘Inside Tract’ magazine. Read the full article here

READ MORE >
April 20th, 2018

Qu Biologics begins Phase 2 Clinical Trial in Crohn’s disease

Qu Biologics Inc. (Qu), a Vancouver, Canada-based biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore innate immune function, is pleased to announce the receipt of a ‘No Objection Letter’ (NOL) from Health Canada and the initiation of their follow-on Phase 2 clinical trial to study QBECO SSI for […]

READ MORE >
April 4th, 2018

Julia Levy – a trailblazer for women in STEM

A woman of wisdom and influence and we’re proud to be associated – Julia Levy is a member of Qu Biologics Board of Directors and has blazed a trail for women in STEM. Read more about her journey here .  

READ MORE >
March 21st, 2018

Protected: IBD Advisory Panel meeting March 6 2018

There is no excerpt because this is a protected post.

READ MORE >
December 20th, 2017

Qu Biologics invited to present research data at inaugural Crohn’s and Colitis Congress

Vancouver, British Columbia – Dec 19th, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system is pleased to report that they will be presenting clinical outcome data from Qu’s recently completed Phase 2 study in ulcerative colitis at […]

READ MORE >

Past events:


Past events: